by Robert Hayes Posted on July 3, 2021July 3, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Acquires Vigene Biosciences For $292.5 Million Read More
by Robert Hayes Posted on May 17, 2021May 17, 2021 BUSINESS BRIEF: Wilmington’s Charles River Labs To Acquire Vigene Biosciences To Enhance Gene Therapy Capabilities Read More
by Robert Hayes Posted on April 6, 2021April 6, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Completes Acquisition Of Cognate BioServices For $875 Million Read More
by Robert Hayes Posted on April 5, 2021April 5, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Acquires Retrogenix Read More
by Robert Hayes Posted on March 1, 2021February 28, 2021 BUSINESS BRIEF: Charles River Labs Announces Strategic Partnership With Kibur Medical To Advance Preclinical Oncology Studies Read More
by Robert Hayes Posted on February 21, 2021February 21, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories To Acquire Cognate BioServices For $875 Million Read More
by Robert Hayes Posted on February 3, 2021February 1, 2021 BUSINESS BRIEF: Wilmington’s Charles River Announces Strategic Partnership With Cypre, Expands 3D In Vitro Services For Cancer Immunotherapy & Targeted Therapy Drug Screening Read More
by Robert Hayes Posted on January 16, 2021January 16, 2021 BUSINESS BRIEF: Charles River Partners With JADE Biomedical To Expand Biologics Capabilities Read More
by Robert Hayes Posted on January 5, 2021January 5, 2021 BUSINESS BRIEF: Wilmington’s Charles River Laboratories Acquires Distributed Bio Read More
by Robert Hayes Posted on October 16, 2020October 17, 2020 Wilmington’s Charles River Laboratories Adds George Llado To Board Of Directors Read More
Wilmington Apple 
You must be logged in to post a comment.